Current Problems in Pediatric and Adolescent Health Care
Volume 37, Issue 4 , Pages 118-135 , April 2007

Update on Therapeutic Monoclonal Antibodies

  • James B. Bussel, MD

      Affiliations

    • Department of Pediatrics, Cornell University School of Medicine, New York, New York
    • ,
  • Lisa Giulino, MD

      Affiliations

    • Department of Pediatrics, Cornell University School of Medicine, New York, New York
    • ,
  • Susan Lee, MD

      Affiliations

    • Department of Medicine, the University of California at San Diego, San Diego, California
    • ,
  • Vivek L. Patel, BS

      Affiliations

    • Department of Pediatrics, Cornell University School of Medicine, New York, New York
    • ,
  • Christy Sandborg, MD

      Affiliations

    • Department of Pediatrics, Stanford University School of Medicine, Stanford, California
    • ,
  • E. Richard Stiehm, MD

      Affiliations

    • Department of Pediatrics, the University of California at Los Angeles, Los Angeles, California.

References 

  1. Ballow M. -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?. J Allergy Clin Immunol. 2005;62:12–18
  2. Liossis SC, Tsokos GC. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol. 2005;116:721–729
  3. Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 200,116:731-36.
  4. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357
  5. Ansell BM. Prognosis in juvenile arthritis. Adv Exp Med Biol. 1999;455:27–33
  6. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989–1999
  7. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2006;20:279–300
  8. Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci. 2004;25:201–209
  9. Tracey KJ, Lowry SF, Fahey TJ, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164:415–422
  10. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet. 1997;349:1912–1913
  11. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis. 1999;58(Suppl 1):I32–I39
  12. Woo P. The cytokine network in juvenile chronic arthritis. Rheum Dis Clin North Am. 1997;23:491–498
  13. Murray KJ, Grom AA, Thompson SD, Lieuwen D, Passo MH, Glass DN. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol. 1998;25:1388–1398
  14. Isomaki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med. 1997;29:499–507
  15. Berman MA, Sandborg CI, Wang Z, et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol. 1996;157:4690–4696
  16. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:1670–1676
  17. De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol. 1992;10:493–498
  18. De Benedetti F, Meazza C, Martini A. Role of interleukin-6 in growth failure: an animal model. Horm Res. 2002;58(Suppl 1):24–27
  19. De Benedetti F, Meazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142:4818–4826
  20. Lovell DJ, Giannini EH, Reiff A, et al. Pediatric Rheumatology Collaborative Study Group for the Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–769
  21. Lovell DJ. A randomized, double-blind trial of anti-TNF chimeric monoclonal antibody (infliximab) in combination with methotrexate for the treatment of patients with polyarticular course JRA. Arthritis Rheum. 2005;52:S724
  22. Lovell DJRN, Jung L, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results. Arthritis Rheum. 2006;54:S303
  23. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? (An update on safety). J Rheumatol Suppl. 2002;65:33–38
  24. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 2002;16:183–200
  25. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002;65:16–21
  26. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–1486
  27. Irigoyen POJ, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum. 2004;50:S437
  28. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101
  29. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52
  30. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28:231–238
  31. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–1400
  32. Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl. 2006;77:24–28
  33. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–876
  34. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817–826
  35. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res. 2001;7:709–723
  36. Flieger D, Renoth S, Beier I, et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204:55–63
  37. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445
  38. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673–683
  39. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232–239
  40. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:3266–3274
  41. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assn J. 2002;4:1006–1008
  42. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511–1513
  43. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857–3861
  44. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–2642
  45. Taube T, Schmid H, Reinhard H, von Stackelberg A, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90:281–283
  46. Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–221
  47. Binstadt BA, Caldas AM, Turvey SE, et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr. 2003;143:598–604
  48. Cvetkovic RS, Perry CM. Spotlight on rituximab in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Biodrugs. 2006;20:253–257
  49. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res. 2006;20:915–928
  50. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–2170
  51. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883–888
  52. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997;349:1531–1536
  53. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78:275–280
  54. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenicpurpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Hematol. 2002;69:95–100
  55. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol. 2003;74:263–267
  56. Penalver FJ, Jimenez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400–406
  57. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Sem Oncol. 2000;27(6 Suppl 12):99–103
  58. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002;87:189–195
  59. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel J. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year. Blood. 2006;108:145–146(abstract).
  60. Perrotta AL. Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost. 2006;12:97–100
  61. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med. 2007;146:25–33
  62. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol. 2001;80:549–552
  63. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol. 2006;155:1053–1056
  64. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood. 2002;99:1486–1488
  65. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 2002;100:1104–1105
  66. Steurer M, Clausen J, Gotwald T, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation. 2003;76:435–436
  67. Carreno L, Lopez-Longo FJ, Monteagudo I, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8:287–292
  68. Mok CC. Emerging drug therapies for systemic lupus erythematosus. Exp Opin Emerg Drugs. 2006;11:597–608
  69. Seelen MA, Daha MR. The role of complement in autoimmune renal disease. Autoimmunity. 2006;39:411–415
  70. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med. 2007;146:25–33
  71. Stasi R, Pagano A, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957
  72. Binstadt BA, Caldas AM, Turvey SE, et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr. 2003;143:598–604
  73. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res. 2006;20:915–928
  74. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assn J. 2002;4:1006–1008
  75. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel J. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year. Blood. 2006;108:145–146(abstract).
  76. Perrotta AL. Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost. 2006;12:97–100
  77. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511–1513
  78. Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90:281–283
  79. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune disease. Leuk Lymphoma. 2003;44:1951–1955
  80. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857–3861
  81. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol (Berlin). 2005;20:811–813
  82. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005;52:3168–3174
  83. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005;17:550–557
  84. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Eheum. 2006;54:2970–2982
  85. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148:623–627
  86. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999;169:107–121
  87. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol. 1998;160:51–59
  88. Chan OT, Madaio MP, Shlomchik MJ. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol. 1999;163:3592–3596
  89. Narat S, Gandia J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005;90:1273–1274
  90. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–1492
  91. Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006;15:223–231
  92. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44:1542–1545
  93. ten Cate R, Smiers FJ, Bredius RG, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford). 2004;43:244
  94. Cvetkovic RS, Perry CM. Spotlight on rituximab in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Bio Drugs. 2006;20:253–257
  95. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol. 2007;(in press)
  96. Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004;124:787–795
  97. Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(Suppl 31):S203–S208
  98. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19–31
  99. Kavanaugh A, Cush JJ, Matteson E. ACR Hotline. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis (Part II. CHF, infection and other safety issues). 2003;Aug. http://www.rheumatology.org/publications/hotline (Accessed July 20, 2006).
  100. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Prac Res Clin Rheumatol. 2003;17:345–363
  101. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–1419
  102. Weinblatt M, Combe B, White A, et al. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDS: 1-year results of the ASSURE trial. [abstract] Ann Rheum Dis. 2005;64(Suppl 111):60
  103. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565–2570
  104. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a neutralizing agents. Arthritis Rheum. 2003;48:319–324
  105. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099–1100
  106. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor a antagonists. Arthritis Rheum. 2004;50:1959–1966
  107. Crnkic M, Saxne T, Sjoholm A, et al. Response to pneumococcal vaccination in patients with rheumatoid arthritis treated with TNF-blockers and/or methotrexate. Arthritis Rheum. 2004;50(9 Suppl):S658
  108. van Vollenhoven RF. Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S122–S125
  109. Kavanaugh A, Cush JJ, Matteson E. ACR Hotline. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis (Part I. Risk of lymphoma with rheumatoid arthritis and TNF inhibitors). 2003;March. Accessed at http://www.rheumatology.org/publications/hotline (Accessed July 20, 2006).
  110. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum. 2002;46:3151–3158
  111. Symmons DPM, Silman AJ. Anti-tumor necrosis factor a therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 2004;50:1703–1706
  112. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis (The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients). Arthritis Rheum. 2004;50:1740–1751
  113. Hyrich KL, Silman AJ, Watson KD, Symmons DPM. Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63(12):1538–1543
  114. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64(5):699–703
  115. Kavanaugh A, Cush JJ. Update on safety issues concerning TNF inhibitors. 2006;May 30. Accessed at http://www.rheumatology.org/publications/hotline (Accessed July 20, 2006).
  116. Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs (TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium). J Pathol. 1999;189:127–137
  117. Kaneko H, Yamada H, Mizuno S, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation tumor necrosis factor-alpha-deficient mice. Lab Invest. 1999;79:379–386
  118. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Prac Res Clin Rheumatol. 2003;17:345–363
  119. Bieber J, Kavanaugh A. Consideration of the risk and treatment of TB in patients with rheumatoid arthritis receiving biologic treatments. Rheum Dis Clin North Am. 2004;30:257–270
  120. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med. 2001;345:1098–1104
  121. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766–1772
  122. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889–894
  123. Magnano MD, Robinson WH, Genovese MC. Demyelination and the use of TNF inhibition. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S134–S140
  124. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism. Arthritis Rheum. 2001;44:1977–1983
  125. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862–2869
  126. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579–580
  127. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol. 2003;22:56–61
  128. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161–3169
  129. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure (Results of the randomized etanercept worldwide evaluation (RENEWAL)). Circulation. 2004;109:1594–1602
  130. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure (Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial). Circulation. 2003;107:3133–3140
  131. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2005;116:305–311
  132. Jacobsson LTH, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–1218
  133. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19–31
  134. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408–1414
  135. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol. 2000;95:2395–2396
  136. Wasserman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, anti-histamine pre-treatment and infusion number. J Rheumatol. 2004;31:1912–1917
  137. Baert F, Noman M, Verneire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608
  138. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001;28:1238–1244
  139. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept. Arch Dermatol. 2001;137:893–899
  140. Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis. 2005;64(Suppl 4):iv18–iv23
  141. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–2392
  142. Chambers SA, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune disease. Lupus. 2005;14:210–214
  143. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–473
  144. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum-sickness after rituximab treatment. Ann Oncol. 2003;14:1792
  145. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13:1948–1950
  146. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 2002;70:329
  147. D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44:1717–1718
  148. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224
  149. Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy. 2005;25:1151–1155
  150. Ursell MR, O’Connor PW. Natalizumab and other monoclonal antibodies. Neurol Clin. 2005;23:233–246
  151. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910
  152. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?. Ann Neurol. 2006;60:162–173
  153. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–933
  154. Menter A, Leonardi CL, Sterry W, et al. Long-term management of plaque psoriasis with continuous efalizumamb therapy. J Am Acad Dermatol. 2006;54:S182–S188
  155. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Exp Opin Drug Safety. 2006;5:197–209
  156. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2004;50:1761–1769
  157. Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis (A randomized, double-blind, placebo-controlled, dose escalation trial). Arthritis Rheum. 2002;46:3143–3150
  158. Maini RN, Taylor PC, Pavelka K, et al. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). [abstract] Arthritis Rheum. 2003;48(Suppl):S652
  159. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–R1288
  160. Beyersdorf N, Hanke T, Kerkau T, Hunig T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis. 2005;64:iv91–iv95
  161. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–1028
  162. Sharpe AH, Abbas AK. T-cell costimulation—biology, therapeutic potential, and challenges. N Engl J Med. 2006;355:973–975

PII: S1538-5442(07)00015-6

doi: 10.1016/j.cppeds.2007.02.001

Current Problems in Pediatric and Adolescent Health Care
Volume 37, Issue 4 , Pages 118-135 , April 2007

Article Tools

* Image Usage & Resolution